"Despite advances, access to innovative treatments can be limited, particularly for rare cancers"

Specialised in the discovery and development of novel cell signalling small molecules to treat complex medical conditions, Australian life sciences company QBiotics is currently focusing on novel treatments for cancer and debilitating chronic wounds, along with an early-stage antibiotics programme. While the company is known for its lead product, tigilanol tiglate, which is undergoing clinical trials for various cancers, QBiotics is also actively preparing for a potential IPO on the Australian Securities Exchange (ASX) within this calendar year. To find out more about how QBiotics is tackling some of the most pressing and underserved challenges in global health, BioSpectrum Asia spoke to Stephen Doyle, Chief Executive Officer at QBiotics. Edited excerpts;

- Stephen Doyle

What are the major challenges that QBiotics is addressing through its research projects within Australia and globally?

Many solid tumours, especially rare cancers like soft tissue sarcomas (STS), lack effective, targeted therapies. Existing standards of care - surgery, radiation, and chemotherapy - are often associated with significant morbidity and limited efficacy. Through our tigilanol tiglate programme, we aim to provide a novel, minimally invasive treatment option with the potential to improve patient outcomes and quality of life. Chronic wounds represent a silent epidemic, affecting millions worldwide, and placing immense strain on healthcare systems. Approximately 10 per cent of chronic wounds fail to heal, and with only one new wound healing drug approved in the US in more than two decades, innovation is urgently needed. EBC-1013, our first-in-class small molecule, is designed to activate multiple tissue repair pathways, offering hope for true healing rather than mere wound management. Our early-stage antibiotics programme addresses the growing threat of drug-resistant infections, a looming crisis with profound public health implications. By focusing on these areas, QBiotics is positioned to deliver transformative therapies that address critical gaps in current medical practice, worldwide.

What are the major research projects taking place at QBiotics in 2025? Please share details.

In 2025, we are advancing several pivotal research programmes, each targeting areas of urgent unmet medical need, including: